Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI) filed a Form 8-K on February 7, 2024, to provide a preliminary financial update in connection with Amendment No. 1 to its Registration Statement on Form S-1. The data pertains to the quarter and year ended December 31, 2023. The company notes that its quarter-end financial close process was not yet complete at the time of filing.
Key Financial Metrics
The following preliminary estimates were provided for the period ended December 31, 2023:
- Cash and Cash Equivalents: Approximately $1.9 million.
- Cash Used in Operations: Approximately $27.4 million.
- Indebtedness: Approximately $3.4 million in aggregate principal amount.
The filing does not provide specific values for revenue, net profit, operating margins, or liquidity ratios beyond the cash balance and operating cash burn. The company is classified as an emerging growth company.
Material Changes and Comparisons
The filing text does not provide comparative financial data for the prior period (e.g., the quarter or year ended December 31, 2022) to calculate material changes in revenue, profit, or cash flow. Consequently, year-over-year or quarter-over-quarter trends cannot be determined from this document.
Guidance, Outlook, and Risks
Management Commentary: Management emphasizes that the reported figures are preliminary, unaudited, and subject to change upon completion of financial statement closing procedures. The independent registered public accounting firm has not audited or reviewed these estimates.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers, noting that actual results may vary materially due to risks and uncertainties. Investors are directed to risk factors in the company's Form 10-K and 10-Q filings.
Unusual Items: No specific unusual items or contingencies were detailed in this summary, other than the preliminary nature of the financial data.
Investor Verification Checklist
- Verify the final audited cash balance and operating cash flow once the December 31, 2023, financial close is complete.
- Review the full Form S-1 Amendment No. 1 for detailed use of proceeds and capitalization tables.
- Examine the company's most recent Form 10-K and 10-Q for historical trends to contextualize the $27.4 million cash burn.
- Confirm the status of the $3.4 million indebtedness, including maturity dates and interest rates, which are not detailed in this 8-K.